Genegraft

Genegraft is a clinical-stage biotechnology company focused on developing ex vivo gene therapies for severe genetic skin diseases. The company's lead program targets Recessive Dystrophic Epidermolysis Bullosa (RDEB), a devastating condition caused by mutations in the COL7A1 gene. Genegraft's approach involves harvesting a patient's own skin cells, correcting the genetic defect using a retroviral vector to express functional Type VII collagen, and grafting the engineered skin back onto the patient. This personalized regenerative medicine strategy aims to provide long-term healing of chronic wounds and prevent the formation of new blisters.